乙型肝炎病毒血清生物标志物路线图：现状和未来展望

StephenW

乙型肝炎病毒血清生物标志物路线图：现状和未来展望

    Anna Kramvis、Kyong-Mi Chang、Maura Dandri、Patrizia Farci、Dieter Glebe、胡建明、Harry L. A. Janssen、Daryl T. Y. Lau、Capucine Penicaud、Teresa Pollicino、Barbara Testoni、Florian Van Bömmel、Ourania Andrisani、Maria Beumont-Mauviel、Timothy M. Block、Henry L. Y. Chan、Gavin A. Cloherty、William E. Delaney、Anna Maria Geretti、Adam Gehring、Kathy Jackson、Oliver Lenz、Mala K. Maini、Veronica Miller、Ulrike Protzer、Jenny C. Yang、Man-Fung Yuen、Fabien Zoulim 和 Peter A. Reville

Nature Reviews Gastroenterology & Hepatology 第 19 卷，第 727–745 页（2022 年）引用这篇文章

    4358 次访问

    第132章

    指标详情

抽象的

在全球范围内，有 2.96 亿人感染了乙型肝炎病毒 (HBV)，每年约有 100 万人死于与 HBV 相关的原因，包括肝癌。尽管有抑制HBV复制的预防性疫苗和抗病毒疗法，但没有治愈方法。正在加紧努力开发治愈性 HBV 疗法。目前，只有少数生物标志物可用于监测或预测 HBV 疾病进展和治疗反应。随着新疗法的出现，迫切需要新的生物标志物来监测病毒和宿主的反应。 2020 年 10 月，国际消除乙型肝炎病毒联盟 (ICE-HBV) 举办了一场关于 HBV 生物标志物的虚拟互动研讨会，并获得了国际 HBV 会议的认可。来自学术界、临床实践和制药行业的各种利益相关者，具有互补的专业知识，出席并参加了小组讨论。评估了经典和新兴病毒和免疫血清生物标志物在感染过程、疾病进展以及对当前和新兴治疗的反应方面的临床效用。讨论了最新进展，并确定了对 HBV 生物标志物的理解和解释方面的知识差距。本路线图总结了 HBV 生物标志物的优势、劣势、机遇和挑战。
关键点

    随着乙型肝炎病毒 (HBV) 感染的新疗法的出现，迫切需要新的生物标志物来监测病毒和宿主反应。

    本路线图总结了关于慢性 HBV 感染背景下现有和新出现的血清生物标志物的当前知识。

    本路线图讨论了血清 HBV 生物标志物的优势、劣势、机遇和挑战。

    该路线图提供了推进生物标志物快速跟踪所有人的 HBV 治愈所需的前进方向的建议，无论资源、HBV 基因型或疾病阶段如何。

StephenW

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

    Anna Kramvis, Kyong-Mi Chang, Maura Dandri, Patrizia Farci, Dieter Glebe, Jianming Hu, Harry L. A. Janssen, Daryl T. Y. Lau, Capucine Penicaud, Teresa Pollicino, Barbara Testoni, Florian Van Bömmel, Ourania Andrisani, Maria Beumont-Mauviel, Timothy M. Block, Henry L. Y. Chan, Gavin A. Cloherty, William E. Delaney, Anna Maria Geretti, Adam Gehring, Kathy Jackson, Oliver Lenz, Mala K. Maini, Veronica Miller, Ulrike Protzer, Jenny C. Yang, Man-Fung Yuen, Fabien Zoulim & Peter A. Revill

Nature Reviews Gastroenterology & Hepatology volume 19, pages 727–745 (2022)Cite this article

    4358 Accesses

    132 Altmetric

    Metrics details

Abstract

Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.
Key points

    As new therapies for hepatitis B virus (HBV) infection become available, new biomarkers to monitor viral and host responses are urgently needed.

    This Roadmap summarizes current knowledge on existing and emerging serum biomarkers in the context of chronic HBV infection.

    This Roadmap discusses the strengths, weaknesses, opportunities and challenges of serum HBV biomarkers.

    This Roadmap provides suggestions of the way forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage.

StephenW

https://www.nature.com/articles/s41575-022-00649-z.pdf